Robert W Knowles

Title: Innovations in Leukemia Diagnosis by Robert W. Knowles

Introduction

Robert W. Knowles is a notable inventor based in New York, NY (US), recognized for his contributions to the field of medical diagnostics. He has developed a significant patent that enhances the understanding and diagnosis of T cell leukemias. His work is particularly relevant in the context of cancer research and treatment.

Latest Patents

Robert W. Knowles holds a patent for a "Method for differential diagnosis of T cell leukemias using monoclonal antibodies." This innovative method involves the production of two monoclonal antibodies, 3-3 and 3-40, which identify new leukemia-associated antigens. The antibodies have shown reactivity with most cell lines derived from patients with T lymphoblastic leukemia (T-ALL), while not reacting with normal hematopoietic cells. The analysis of fresh leukemic cells revealed that mAb 3-3 specifically reacts with T-ALL cells, whereas mAb 3-40 also interacts with some non-T non-B ALL cells and a few acute myelocytic leukemia (AML) cells. The findings indicate that these antigens can serve as markers for human T-ALL, aiding in the differentiation from other related conditions.

Career Highlights

Robert W. Knowles is affiliated with the Memorial Sloan Kettering Cancer Center, where he continues to contribute to cancer research and diagnostics. His work has implications for improving patient outcomes through more accurate diagnostic methods.

Collaborations

He has collaborated with notable colleagues, including Bo Dupont and Kazuyuki Naito, to advance research in the field of leukemia diagnostics.

Conclusion

Robert W. Knowles' innovative work in developing monoclonal antibodies for leukemia diagnosis represents a significant advancement in medical science. His contributions are vital for enhancing the accuracy of leukemia diagnosis and improving patient care.